TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (OTCBB: ORNI) announced the successful completion of an independently conducted, randomized, double-blind clinical trial on EvoraKids®. The study enrolled sixty 6 to 12 year old, caries-prone children. Trial details and results will be presented on March 21, 2012 at the American Association for Dental Research (AADR) Annual Meeting in Tampa, FL. The study, entitled “DNA-PCR and CRT Results in Children after Probiotic Use”, will be part of an entire scientific session devoted to clinical studies related to dental cariology. The study results demonstrated a statistically-significant decrease from baseline of the levels of the key oral bacterial species, mutans Streptococci and Lactobacilli, after a 4-week treatment with EvoraKids. No adverse events from the use of EvoraKids were reported during the trial.
“Mutans streptococci and Lactobacilli are recognized risk factors in the development of dental caries,” stated Mark Cannon, DDS, the lead author of this independent study. He further stated that he was “delighted to demonstrate that caries-prone children may benefit from the use of probiotics as part of their normal daily dental hygiene regimen.” Dr. Cannon is a faculty member at Northwestern University, an Attending Physician at Children’s Memorial Hospital, Chicago, IL, and a Diplomate of the American Board of Pediatric Dentistry.
John N. Bonfiglio, Ph.D., Chief Executive Officer, commented that “Oragenics is encouraged by the results of this first independent study in children employing the Company’s proprietary blend of oral care probiotics. These data agree with previous results obtained from animal and adult human studies conducted by both Oragenics and independent investigators such as Dr. Cannon, and reinforce the claim that the active ingredient in EvoraKids, ProBiora3®, promotes oral health by helping to maintain a naturally balanced oral microflora.”
EvoraKids is a branded product of Oragenics that contains a special blend of the proprietary oral care ingredient, ProBiora3, and is designed to help support the overall oral health of children between the ages of 3 and 11. The ProBiora3 ingredient is a patented blend of active cultures of three unique strains of beneficial bacteria that are naturally found in healthy mouths.
About Oragenics, Inc.
Oragenics is a leading nutraceutical company focused on oral care probiotics for humans and companion pets. The Company’s proprietary Evora products and ProBiora3 are currently sold in the United States and international markets. In addition, Oragenics has an exciting pipeline of therapeutic products targeting infectious diseases.
About the American Association for Dental Research (AADR)
The AADR is the largest division of the International Association for Dental Research (IADR), with nearly 4,000 members in the United States. To learn more, visit www.aadronline.org. The IADR is a nonprofit organization with more than 11,000 individual members worldwide, dedicated to: (1) advancing research and increasing knowledge to improve oral health, (2) supporting the oral health research community, and (3) facilitating the communication and application of research findings for the improvement of oral health worldwide. To learn more, visit www.iadr.org.
Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect the Company’s current views with respect to future events and financial performance. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project” and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to our ability to raise additional capital to sustain our operations beyond March 31, 2012 and those set forth in our most recently filed annual report on Form 10-K and quarterly report on Form 10-Q, and other factors detailed from time to time in filings with the U.S. Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.
For more information visit www.oragenics.com.
Linda Loren, 813-527-1020
Cooper Global Communications, LLC
Jennifer K. Zimmons, Ph.D., 212-209-7360